NCT00489905View on ClinicalTrials.gov

Study on Evaluation of Zoledronic Acid to Prevent Bone Loss in Men Receiving Androgen Deprivation Therapy for Prostate Cancer

NACompletedINTERVENTIONAL

Enrollment

24

Participants

Timeline

Start Date

April 30, 2005

Study Completion Date

May 31, 2008

Conditions

Prostatic NeoplasmsBone Density

Interventions

DRUG

Zolderonic acid (Zometa)

Trial Locations (1)

Unknown

Department of Urology, Prince of Wales Hospital, Hong Kong

All Listed Sponsors

collaborator

Baxter Healthcare Corporation

INDUSTRY

lead

Hospital Authority, Hong Kong

OTHER_GOV